ArticleVirchows Archiv : an international journal of pathology2025
CD34-positive pleomorphic uterine sarcoma with NUDT3::RAD51B fusion.
Article in Virchows Archiv : an international journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Epithelioid leiomyosarcoma harboring HMGA2::RAD51B fusion: expanding the spectrum of RAD51B-rearranged uterine sarcoma.Virchows Archiv : an international journal of pathology · 2026Article
- The Evolving Molecular Landscape of Uterine Mesenchymal Tumors: Diagnostic and Therapeutic Implications.Cancers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Sarcomas with RAD51B fusions are rare, recently recognized neoplasms that predominantly arise in the uterus. They showed heterogeneous phenotypic features and are typically associated with aggressive biological behaviors. To date, only 14 cases of RAD51B-rearranged sarcomas have been reported in English literature, including 6 perivascular epithelioid cell tumors, 6 leiomyosarcomas, and 2 undifferentiated sarcomas (both uterine in origin). We present an additional case of uterine sarcoma with RAD51B rearrangement. The patient was a 71-year-old woman with a 5.0-cm polypoid mass in the uterine cavity. Histologically, the tumor was composed of spindle to pleomorphic cells arranged in storiform and fascicular patterns within variably myxoid and collagenous stroma. The neoplastic cells had vesicular to hyperchromatic nuclei with occasional multinucleation, with a mitotic rate of 3/10 high-power fields. Notable stromal features included staghorn shaped blood vessels, thick band-like collagen deposition, and prominent chronic inflammatory infiltrates. Immunohistochemically, the tumor cells showed diffuse and strong positivity for CD34, P53, and P16, with focal expression of pan-TRK and smooth muscle actin. Targeted RNA-sequencing revealed NUDT3::RAD51B fusion, which was confirmed by fluorescence in situ hybridization of RAD51B rearrangement. The patient had been free of disease at 22 months' follow-up. This case further illustrates the phenotypic heterogeneity of RAD51B-rearranged sarcomas and expands their clinicopathological and molecular genetic spectrum.
Indexed as
Identifiers
40360859What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.